Dorzolamide Ophthalmic Dosage

This dosage information may not include all the information needed to use Dorzolamide Ophthalmic safely and effectively. See additional information for Dorzolamide Ophthalmic.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Intraocular Hypertension

Instill 1 drop in the affected eye(s) 3 times daily.

Usual Adult Dose for Glaucoma (Open Angle)

Instill 1 drop in the affected eye(s) 3 times daily.

Usual Pediatric Dose for Intraocular Hypertension

Instill 1 drop in the affected eye(s) 3 times daily.

Usual Pediatric Dose for Glaucoma (Open Angle)

Instill 1 drop in the affected eye(s) 3 times daily.

Renal Dose Adjustments

Not recommended for patients with severe renal impairment (CrCl less than 30 mL/min).

Liver Dose Adjustments

Caution is recommended in patients with hepatic impairment.

Precautions

Remove contact lenses before administration and wait at least 15 minutes before reinserting them.

Wait at least 10 minutes before instilling other eyedrops.

Patients should be advised to notify their physician immediately and discontinue the drug if they experience ocular reactions, especially conjunctivitis and lid reactions, hypersensitivity reactions, or other serious reactions. Patients should also be advised to contact their physician immediately if they develop other ocular conditions (e.g., infection, trauma), or have eye surgery.

Additive systemic effects may occur with dorzolamide and oral carbonic anhydrase inhibitors and concomitant administration is not recommended.

Patients should be instructed to avoid allowing the tip of the container to contact the eye, eyelid, fingers or any other surface to avoid contamination.

Dorzolamide is a sulfonamide and although administered topically is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. Patients should be advised that if serious or unusual reactions including severe skin reactions or signs of hypersensitivity occur, they should discontinue the use of the product.

Dialysis

Not recommended for patients with severe renal impairment (CrCl <30 mL/min).

Hide
(web1)